This work arose in response to the need for a sensitive, cost-effective method of screening for pulmonary arterial hypertension (PAH) which occurs in up to 15% of patient with scleroderma. PAH is one of the leading causes of mortality and is one of the major determinants of the substantial healthcare costs associated with scleroderma. International guidelines recommend annual screening for PAH in all patients with scleroderma as while early detection can be challenging, screening is associated with better outcomes. Transthoracic echocardiogram (TTE) alone is insufficiently sensitive for identifying patients at risk of PAH who should be referred for right heart catheterisation (RHC), the gold standard for PAH diagnosis. The DETECT algorithm involved more disease-related features and is still dependent on a TTE.